Strong evidence · Grade A
Dulaglutide
Dulaglutide (Trulicity)
Score
82 / 100
Half-life
~5 days
Brand
Trulicity
FDA
2014
TL;DR
01
A once-weekly GLP-1 receptor agonist, FDA-approved as Trulicity for type 2 diabetes (2014; later in children 10 and older). It is built as a GLP-1 analog fused to an antibody fragment, which is what lets it be dosed weekly.
02
In the REWIND cardiovascular outcomes trial — notable for a mostly primary-prevention population — dulaglutide cut major cardiovascular events by 12%.
03
It is a diabetes drug first: weight loss is modest (roughly 3 kg at 1.5 mg), and it is not FDA-approved for obesity.
04
Head-to-head, it was beaten by semaglutide on both blood sugar and weight (SUSTAIN 7), consistent with its place behind the newer agents for weight-focused use.
05
Main side effects are gastrointestinal; it carries the class boxed warning for thyroid C-cell tumors and is contraindicated with a personal/family history of medullary thyroid cancer or MEN2.
CV events (REWIND)
−12%
MACE, HR 0.88 · Lancet 2019
HbA1c (AWARD program)
≈ −1.5 pp
vs baseline · phase 3
Weight (1.5 mg)
≈ −3 kg
modest, diabetes population
vs semaglutide (SUSTAIN 7)
−3.0 vs −6.5 kg
Lancet D&E 2018 · 40 wk
Dosing
Once weekly
~5-day half-life, subcutaneous
Part 01 · How it works
Mechanism.
Dulaglutide is a GLP-1 receptor agonist — the same appetite-and-insulin pathway as semaglutide and liraglutide — but built by fusing the GLP-1 peptide to a piece of an antibody. That bulky attachment slows its clearance so it lasts about five days, allowing once-weekly dosing. It lowers blood sugar well and reduces cardiovascular risk, but its weight-loss effect is smaller than the newer agents, which is why it's positioned mainly for diabetes.
Same appetite-and-insulin dial as the other GLP-1 drugs, bolted onto an antibody 'anchor' so one weekly dose lasts. It's a steady diabetes workhorse rather than a weight-loss standout.
GLP-1R agonism
Agonist at the GLP-1 receptor — glucose-dependent insulin secretion, delayed gastric emptying, appetite suppression.
IgG4-Fc fusion
The GLP-1 analog is fused to a modified human IgG4-Fc fragment, extending the half-life to ~4.7 days and reducing immunogenicity.
Cardiovascular effect
In REWIND, reduced major adverse cardiovascular events in a largely primary-prevention type 2 diabetes population.
Weight profile
Weight loss is real but modest relative to semaglutide and tirzepatide; higher doses (AWARD-11) add some effect.
Part 02 · Dosing & administration
How it's taken.
Clinical · trial-validatedValues below describe how Dulaglutide has been administered in human clinical trials and/or approved labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Start
0.75 mg
Weekly starting dose for type 2 diabetes (Trulicity).
Step-up
1.5 mg
Common maintenance dose; escalate if further glycemic control is needed.
TARGET
Higher doses
3.0–4.5 mg
AWARD-11 higher doses add some HbA1c and weight effect.
·
Doses below are values from labeling and trials, not instructions.
·
Dulaglutide is approved for type 2 diabetes, not obesity; weight loss is a secondary effect.
·
Once-weekly subcutaneous; the pen delivers a fixed dose and does not require dose measuring.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Nausea
Dose-dependent; most common early and usually attenuates.
~12–29%
Diarrhea
Common, generally mild-to-moderate.
~9–17%
Vomiting
More likely at higher doses.
~6–17%
Abdominal pain / dyspepsia
Part of the GI cluster.
Common
Injection-site reactions
Generally mild; lower immunogenicity from the IgG4-Fc design.
Uncommon
Serious · rare
Thyroid C-cell tumors (boxed warning)
Class boxed warning; contraindicated with personal/family history of MTC or MEN2. Human relevance unconfirmed.
Rodent finding
Acute pancreatitis
Discontinue for persistent severe abdominal pain radiating to the back.
<1%
Gallbladder disease
Cholelithiasis, associated with the class and with rapid weight change.
Uncommon
Hypoglycemia (in combination)
Risk rises mainly with concomitant insulin or a sulfonylurea.
Dose-dependent
Absolute · do not use
×
Personal or family history of medullary thyroid carcinoma (FDA boxed warning)
×
Multiple endocrine neoplasia syndrome type 2 (MEN2) (FDA boxed warning)
×
Known serious hypersensitivity to dulaglutide or any product component
×
History of pancreatitis (use with caution)
×
Pregnancy or breastfeeding
×
Concurrent use of another GLP-1 receptor agonist
Relative · discuss first
!
Personal or family history of medullary thyroid carcinoma or MEN2 — boxed contraindication, not merely relative
!
History of pancreatitis — discuss with GI / endocrinology first
!
Pregnancy or breastfeeding — discontinue if pregnancy is planned or occurs
!
Severe gastrointestinal disease or gastroparesis — delayed gastric emptying may worsen symptoms
!
Concurrent insulin or sulfonylurea — monitor for hypoglycemia
Interactions
Insulin
Per FDA label: increased risk of hypoglycemia; consider reducing the insulin dose when starting dulaglutide
Major
Sulfonylureas
Per FDA label: increased risk of hypoglycemia; consider a sulfonylurea dose reduction
Major
Oral medications (general)
Per FDA label: dulaglutide slows gastric emptying and may affect the rate of absorption of co-administered oral drugs; monitor where timing or narrow therapeutic index matters
Moderate
Other GLP-1 receptor agonists
Overlapping mechanism with no added benefit and increased GI and hypoglycemia risk; not recommended together
Major
Labs to monitor
HbA1c
Baseline and every 3 months
Primary glycemic marker when used for diabetes
Fasting Glucose
Baseline and periodically
Track glycemic response and hypoglycemia risk, especially with insulin or sulfonylureas
Lipase & Amylase
Baseline and if abdominal symptoms occur
Pancreatitis screening (GLP-1 class concern)
Comprehensive Metabolic Panel
Baseline and every 3-6 months
Kidney function and gallbladder/liver screening, particularly with significant GI fluid loss
Urine Albumin-to-Creatinine Ratio
Baseline and annually or as indicated
Diabetic kidney monitoring; REWIND tracked albuminuria changes
Part 04 · Evidence
How strong is the evidence?
82
Grade A
Grade A. A long-approved diabetes agent with a large, mostly primary-prevention cardiovascular outcomes trial (REWIND) and a deep phase 3 program (AWARD). The caveat is scope: for weight specifically it is modest and unapproved, and it loses head-to-head to semaglutide.
Mechanistic plausibility
Well-established GLP-1 biology; the antibody-fusion design is validated by a decade of use.
88
Human evidence
Extensive AWARD phase 3 program plus the REWIND CVOT — with an unusually broad primary-prevention population.
90
Safety & tolerability
GI-dominant and mostly transient; boxed thyroid C-cell warning; long real-world track record.
80
Durability
Durable glycemic and CV benefit; weight regain on discontinuation as with the class.
76
Independence
Pivotal trials Eli Lilly-sponsored, but corroborated by independent meta-analyses and long post-marketing experience.
72
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2019
The Lancet Industry funded
REWIND — cardiovascular outcomes with dulaglutide in type 2 diabetes
12% relative reduction in major adverse cardiovascular events (HR 0.88); benefit seen in a population that was predominantly primary prevention, broadening applicability.
RCT CVOT, median 5.4 yr, placebo-controlled · n = 9,901 · Funded by Eli Lilly; large, long, event-driven trial with a broad population.
PMID 31189511 ↗
High
02
2018
The Lancet Diabetes & Endocrinology Industry funded
SUSTAIN 7 — semaglutide vs dulaglutide once weekly
Semaglutide superior on both HbA1c and weight: at the higher doses, −6.5 kg (semaglutide 1.0 mg) vs −3.0 kg (dulaglutide 1.5 mg); HbA1c −1.8 vs −1.4 pp.
Phase 3b RCT, 40 wk, open-label head-to-head · n = 1,201 · Funded by Novo Nordisk (maker of the winning comparator); open-label design. Places dulaglutide behind semaglutide within the class.
PMID 29397376 ↗
High
03
2014
The Lancet Industry funded
AWARD-6 — dulaglutide 1.5 mg vs liraglutide 1.8 mg
Once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg for HbA1c reduction, with comparable safety.
Phase 3 RCT, 26 wk, open-label non-inferiority · n = 599 · Funded by Eli Lilly; established weekly dulaglutide as glycemically competitive with a daily benchmark.
PMID 25018121 ↗
High
04
2024
Cureus Flagged
Semaglutide vs other GLP-1 agonists for weight loss in type 2 diabetes — meta-analysis
Across trials, semaglutide produced greater weight loss than other GLP-1 agonists including dulaglutide, reinforcing dulaglutide's modest weight profile.
Systematic review and meta-analysis · Independent synthesis; heterogeneous source trials and mostly indirect comparisons.
PMID 39385875 ↗
Moderate
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Beaten head-to-head by semaglutide
Lost head-to-head Lancet D&E (SUSTAIN 7) · 2018
In a direct phase 3b comparison, semaglutide beat dulaglutide on both glycemic control and weight — −6.5 kg vs −3.0 kg at the higher doses, with a similar safety profile.
What this means: For patients where weight loss is a priority, dulaglutide is a second choice within its own class. Its strengths are the CV outcome data and a long safety record, not weight efficacy.
PMID 29397376 ↗
02
Modest weight effect and no obesity indication
Mechanism limit Cureus (meta-analysis) · 2024
Dulaglutide's weight loss (~3 kg at 1.5 mg) is modest and consistently below semaglutide across trials; it is not FDA-approved for weight management and any weight-focused use is off-label.
What this means: As a weight-loss tool it underperforms the front-line agents. It is best understood as a cardiometabolic diabetes drug that also trims some weight, not a dedicated obesity therapy.
PMID 39385875 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
FDA-approved
Rx as Trulicity for type 2 diabetes (adults and children 10+). Not approved for weight management; weight-focused use is off-label.
~$800–1,000/mo cash; often lower with diabetes coverage
European Union
Approved
Approved as Trulicity for type 2 diabetes; prescription-only.
Varies by country and reimbursement
United Kingdom
Approved
Trulicity available on the NHS for type 2 diabetes within prescribing criteria.
NHS-covered where criteria met
Canada
Approved
Approved as Trulicity for type 2 diabetes; prescription-only.
Varies by province and private coverage
The Peptide Column takes no affiliate commission from any source. Dulaglutide is a prescription-only medicine approved for type 2 diabetes; it is not approved for weight loss. We link only to clinician-directed access, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Am I a candidate for dulaglutide for blood-sugar control, and how does it compare with once-weekly semaglutide or tirzepatide?
02
What weekly dose-escalation schedule should I follow (0.75 mg up to 4.5 mg), and how are nausea and other GI effects managed?
03
What are my risks for pancreatitis, gallbladder disease, and the thyroid C-cell concern in the boxed warning, given my history?
04
How long is treatment expected to continue, and what happens to my blood sugar or weight if I stop?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. REWIND — cardiovascular outcomes with dulaglutide in type 2 diabetes · The Lancet, 2019 · PMID 31189511 ↗
- 02. SUSTAIN 7 — semaglutide vs dulaglutide once weekly · The Lancet Diabetes & Endocrinology, 2018 · PMID 29397376 ↗
- 03.
- 04. Semaglutide vs other GLP-1 agonists for weight loss in type 2 diabetes — meta-analysis · Cureus, 2024 · PMID 39385875 ↗
- 05.
- 06.